Multiregional transcriptomics identifies congruent consensus subtypes with prognostic value beyond tumor heterogeneity of colorectal cancer.

Intra-tumor heterogeneity compromises the clinical value of transcriptomic classifications of colorectal cancer. We investigated the prognostic effect of transcriptomic heterogeneity and the potential for classifications less vulnerable to heterogeneity in a single-hospital series of 1093 tumor samples from 692 patients, including multiregional samples from 98 primary tumors and 35 primary-metastasis sets. We show that intra-tumor heterogeneity of the consensus molecular subtypes (CMS) is frequent and has poor-prognostic associations independently of tumor microenvironment markers.

Phylogeny and Cryptic Diversity of (Onuphidae, Annelida) in the East Atlantic.

Audouin & Milne-Edwards, 1833 is a species rich genus that is common in tropical and subtropical regions. The genus is readily identified by its striking, spiral branchiae, but species identification has historically been challenging due to a high variation in diagnostic characters used. This study aims to reconstruct the phylogeny of with molecular markers and assess the species diversity of West African with the species delimitation programs bPTP and BPP.

Genomic and prognostic heterogeneity among RAS/BRAF /TP53 co-mutated resectable colorectal liver metastases.

Hepatic resection is potentially curative for patients with colorectal liver metastases, but the treatment benefit varies. KRAS/NRAS (RAS)/TP53 co-mutations are associated with a poor prognosis after resection, but there is large variation in patient outcome within the mutation groups, and genetic testing is currently not used to evaluate benefit from surgery. We have investigated the potential for improved prognostic stratification by combined biomarker analysis with DNA copy number aberrations (CNAs), and taking tumor heterogeneity into account.

Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer.

Background: There is a need for improved selection of patients for adjuvant chemotherapy after resection of non-metastatic colorectal cancer (CRC). Regulator of chromosome condensation 2 (RCC2) is a potential prognostic biomarker. We report on the establishment of a robust protocol for RCC2 expression analysis and prognostic tumour biomarker evaluation in patients who did and did not receive adjuvant chemotherapy.

Exploratory analyses of consensus molecular subtype-dependent associations of mutations with immunomodulation and prognosis in colorectal cancer.

Background: Accumulating evidence suggests immunomodulatory and context-dependent effects of mutations in cancer. We performed an exploratory analysis of the transcriptional, immunobiological and prognostic associations of mutations within the gene expression-based consensus molecular subtypes (CMSs) of colorectal cancer (CRC).

Materials And Methods: In a single-hospital series of 401 stage I-IV primary CRCs, we sequenced the whole coding region of and analysed CMS-dependent transcriptional consequences of the mutations by gene expression profiling.